Vivistim System
Mobia Medical, Inc. · Decision date Aug 27, 2021
What did the FDA approve?
FDA records P210007 as an original PMA application. The recorded decision is approval, dated Aug 27, 2021.
FDA approval order statement
Approval the MicroTransponder Vivistim Paired VNS System (Vivistim System) is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Physical Medicine
- Decision date
- Aug 27, 2021
Regulatory record facts
- Identifier
- P210007
- Regulatory pathway
- Premarket approval application
- Applicant
- Mobia Medical, Inc.
- Product code
- QPY
- Decision code
- APPR
- Decision date
- Aug 27, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for stroke rehabilitation.
- Applicant
- Mobia Medical, Inc.
- Product code
- QPY
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210007 received
Application receipt date recorded by FDA.
P210007 · FDA decision
APPR
P210007/S007 · Related supplement
Vivistim System
P210007/S010 · Related supplement
Vivistim System
P210007/S008 · Related supplement
Vivistim Paired VNS System
P210007/S011 · Related supplement
Vivistim System
P210007/S012 · Related supplement
Vivistim Paired VNS System
P210007/S013 · Related supplement
Vivistim System
P210007/S014 · Related supplement
Vivistim Pair VNS System
P210007/S015 · Related supplement
Vivistim System
Timeline entries are records held by MedtechLedger for P210007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Vivistim SystemP210007/S007 | Mobia Medical, Inc. | PMA supplement | Sep 3, 2025 | FDA |
Vivistim SystemP210007/S010 | Mobia Medical, Inc. | PMA supplement | Jan 28, 2026 | FDA |
Vivistim Paired VNS SystemP210007/S008 | Mobia Medical, Inc. | PMA supplement | Feb 26, 2026 | FDA |
Vivistim SystemP210007/S011 | Mobia Medical, Inc. | PMA supplement | Mar 2, 2026 | FDA |
Vivistim Paired VNS SystemP210007/S012 | Mobia Medical, Inc. | PMA supplement | Apr 1, 2026 | FDA |
Vivistim SystemP210007/S013 | Mobia Medical, Inc. | PMA supplement | Apr 10, 2026 | FDA |
Vivistim Pair VNS SystemP210007/S014 | Mobia Medical, Inc. | PMA supplement | Jun 18, 2026 | FDA |
Vivistim SystemP210007/S015 | Mobia Medical, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Mobia Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2802 Flintrock Trace, Suite 226, Austin, TX, 78738
Sources and methodology
- Original FDA record: P210007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




